People with obesity who had been on a GLP-1 medicine for at least six months had fewer in-hospital complications after hip fracture surgery in one hospital registry study. The study compared patient records, so it could not determine whether the medicine caused the difference [1].
What the study compared
Our guide to GLP-1 use and hip fracture risk covers whether fractures occur. This study looked at what happened after a fracture. The researchers used a prospective registry from a single institution covering 2014–2024. They matched patients by age, fracture pattern and other health conditions [1].
Complications and readmissions after surgery
Among patients with obesity, the overall in-hospital complication rate was 22.41% with GLP-1 use, compared with 60.34% without it (P < 0.001 across the four groups). The rates were 55.17% at normal weight and 51.72% with overweight. Minor complication rates were 17.24% with GLP-1 use, 48.28% with obesity and no GLP-1 use, 37.93% at normal weight and 51.72% with overweight. The differences across the four groups were statistically significant for both measures [1].
The study reported higher readmission rates in the group with obesity that did not use a GLP-1: 17.24% at 30 days and 24.14% at 90 days. The analysis did not detect significant differences in major complications or implant failure [1].
Our guide to GLP-1 medicines before surgery addresses medication planning for procedures. This registry study recorded prior use at the time of injury and did not test starting or stopping treatment around surgery.